On October 1, 2021 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 36TH Annual Meeting (SITC 2021) taking place November 10-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C (Press release, Neoleukin Therapeutics, OCT 1, 2021, View Source [SID1234590657]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Presentations by our scientists and collaborators at SITC (Free SITC Whitepaper) 2021 will highlight promising preclinical data with NL-201, a fully de novo IL-2/IL-15 agonist, currently in phase 1 clinical development," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We look forward to sharing data on the ability of NL-201 to activate the tumor microenvironment, to demonstrate antitumor activity via intratumoral administration, and to be combined with novel therapeutic candidates."
Details of the poster presentations are as follows:
Title: NL-201 Induces Inflammation in a ‘Cold’ Tumor Microenvironment through Upregulation of MHC-I, Expansion of the TCR Repertoire, and Potent Antitumor Activity when Combined with PD-1 Inhibition
Poster/Abstract Number: 716
Date/Time: Saturday, November 13, 5 a.m. to 8:30 p.m., ET
Title: Intratumoral Administration of NL-201, an Alpha-Independent IL-2/15 Receptor Agonist, Inhibits the Growth of Both Injected and Uninjected Tumors in Preclinical Models
Poster/Abstract Number: 898
Date/Time: Saturday, November 13, 5 a.m. to 8:30 p.m., ET
Title: A First-in-Human Phase 1 Study of NL-201 in Patients with Relapsed or Refractory Cancer (Trials in Progress)
Poster/Abstract: 509
Date/Time: Friday, November 12, 5 a.m. to 8:30 p.m. ET
Title: ICT01, an Anti-BTN3A Monoclonal Antibody, and NL-201, an Alpha-Independent IL-2/IL-15 Agonist, Combine to Elicit a Potent Anti-Tumor Response by Synergistically Stimulating g9d2 T Cell Activation and Proliferation
Poster/Abstract Number: 563
Date/Time: Friday, November 12, 5 a.m. to 8:30 p.m. ET
Poster presentations will be accessible in person and virtually. Onsite posters will be displayed in the SITC (Free SITC Whitepaper) Poster Hall located in Hall E of the convention center. ePosters will be available for SITC (Free SITC Whitepaper) attendees on Nov. 12 at 7 am ET and can be accessed on the SITC (Free SITC Whitepaper) virtual meeting site. All attendees will receive information on how to access the site after they have registered.
About NL-201
NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without any bias toward cells expressing the alpha receptor subunit (CD25). Previously presented preclinical data has demonstrated the ability of NL-201 to stimulate and expand CD8+ and NK cells at low doses with minimal impact on immunosuppressive regulatory T cells. Furthermore, NL-201 has demonstrated both monotherapy and combination activity across a wide range of preclinical syngeneic tumor models.